tbuckley/cabot-search huggingface dataset:
Synopsis of Human Anatomy.
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Novel Method to Enhance Sternal Healing After Harvesting Bilateral Internal Thoracic Arteries With Use of Basic Fibroblast Growth Factor
Authors: Atsushi Iwakura, Yasuhiko Tabata, Manabu Miyao, Makoto Ozeki, Nobushige Tamura, Akio Ikai, Kazunobu Nishimura, Tatsuo Nakamura, Yasuhiko Shimizu, Masatoshi Fujita, Masashi Komeda
Journal: Circulation (2000)

Background —Poor healing of the sternum often limits the use of bilateral internal thoracic arteries (BITAs) in coronary bypass surgery, especially for diabetic patients. We have reported that basic fibroblast growth factor (bFGF) enhanced regeneration of the skull. This study was designed to evaluate the effects of topical use of bFGF on sternal healing after removing the BITAs. Methods and Results —Forty-five Wistar rats were subjected to median sternotomy and were divided into 3 groups: 15 had the BITAs removed and had a bFGF sheet applied on the posterior table of the sternum (group A), 15 had just the BITAs removed (group B), and 15 had intact BITAs (group C). Five and 10 rats were euthanized 2 and 4 weeks after surgery, respectively, in all 3 groups. Peristernal blood flow, measured with use of a noncontact laser flowmeter, decreased after removal of the BITAs ( P &lt;0.001). Four weeks after the surgery, PBF markedly increased only in group A (9.7±1.2, 6.5±0.6, and 8.2±0.5 mL · min −1 · 100 g −1 for groups A, B, and C, respectively; P &lt;0.01 by ANOVA). Four weeks after surgery, the following findings were obtained only in group A: (1) nearly completely healed sternum filled with regenerated bone tissue, (2) marked angiogenesis around the sternum, and (3) osteoblasts in an active form around the edge of the sternum. Conclusions —The results suggest that use of the bFGF sheet offset the sternal ischemia and accelerated sternal healing. This method may help to decrease sternal necrosis in high-risk patients or allow extended use of BITAs in coronary bypass surgery.
Therapeutische Technik
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nutrition matters
Authors: F. Godlee
Journal: BMJ (2014)

The cellular proteasome is an important molecular target in cancer therapy and drug resistance research. Proteasome inhibitors are effective agents against multiple myeloma and mantle cell lymphoma and display great potential as treatment for a variety of other malignancies. The proteasome is a large multicatalytic, proteinase complex located in the cytosol and the nucleus of eukaryotic cells. The ubiquitin proteasome system is responsible for the degradation of most intracellular proteins and therefore plays an essential regulatory role in critical cellular processes including cell cycle progression, proliferation, differentiation, angiogenesis, and apoptosis. Cancer cells are particularly sensitive to proteasome inhibitors, indicating the utility for inhibition of the ubiquitin-proteasome pathway as an approach for cancer therapy.
Use of diazepam in hallucinogenic drug crises
Authors: L. P. Solursh
Journal: JAMA (1968)

The increasing spread of hallucinogenic-drug compounds with atropine-like action presents problems for physicians in North American urban areas. Dangers of using phenothiazines in treatment programs are no longer restricted to 5-dimethoxy-4-methyl-amphetamine (STP), but also to more routinely used illegal compounds. The doctor must assume that such drugs may be combined with a chemical having atropine-like action. Diazepam was used in the treatment of hallucinogenic-drug crises in 69 patients; 67 responded well. Diazepam seems to be suitable in supportive chemotherapy of "illusinogenic" drug crises.
THE PATHOLOGY OF ATHLETICS.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma
Authors: Venkata Yellapantula, Malin Hultcrantz, Even H. Rustad, Ester Wasserman, Dory Londono, Robert Cimera, Amanda Ciardiello, Heather Landau, Theresia Akhlaghi, Sham Mailankody, Minal Patel, Juan Santiago Medina-Martinez, Juan Esteban Arango Ossa, Max Fine Levine, Niccolo Bolli, Francesco Maura, Ahmet Dogan, Elli Papaemmanuil, Yanming Zhang, Ola Landgren
Journal: Blood Cancer Journal (2020)

A correction to this paper has been published and can be accessed via a link at the top of the paper.
Hypercalcemia associated with oral isotretinoin in the treatment of severe acne
Authors: J. P. Valentic
Journal: JAMA (1983)

ISOTRETINOIN, or 13-<i>cis</i>-retinoic acid, is a derivative of vitamin A that has been found to be of benefit in a number of diseases characterized by abnormal keratinization, including Darier's disease and ichthyosis.<sup>1</sup>It is the most potent inhibitor of sebum secretion known and has been found to be effective in the treatment of severe nodulocystic acne in several trials. Its use has been reported to produce prolonged remission in some patients with severe cystic acne.<sup>2</sup>Although chronic vitamin A intoxication has been associated with hypercalcemia,<sup>3</sup>no similar association has been reported with the use of isotretinoin, to our knowledge. We report herein the occurrence of hypercalcemia in a patient with severe cystic acne treated with oral isotretinoin. <h3>Report of a Case</h3> A 19-year-old man with a two-year history of progressive, severe nodulocystic acne was seen at the University of California, Irvine Medical Center. The disease
Neonatal shivering
Authors: Alistair GS Philip
Journal: The Lancet (1997)

Boris Petrikovsky and colleagues' (Nov 8, p 1366)1Petrikovsky B Silverstein M Schneider EP Neonatal shivering and hypothermia after intrapartum amnioinfusion.Lancet. 1997; 350: 1366-1367Summary Full Text Full Text PDF PubMed Scopus (10) Google Scholar report of neonatal shivering and hypothermia after intrapartum amnioinfusion is unusual, particularly because of the presence of neonatal shivering. One baby was term and the other two were close to term gestation. In 30 years of experience as a neonatologist, I have not witnessed a newborn infant shivering. Maintenance of body temperature in the neonate seems to be predominantly the result of non-shivering thermogenesis, although Brück notes that “shivering has also been observed in the human neonate with severe hypothermia after birth”2Brück K “Neonatal Thermal Regulation” in “Fetal and Neonatal Physiology”.in: Polin RA Fox WW WB Saunders Co, Philadelphia1992: 493Google Scholar I would not classify temperatures of 35·0–35·3°C as severe hypothermia and, therefore, find it surprising that these babies were shivering. At a time when maintaining body temperature of the neonate was not emphasised, Richard Day3Day RL. In “Thermoregulation of the Newly Born”, Suppl No 2 to Reports of Ross Conferences on Pediatric Research, Ross Labs, Columbus, 1964, p 9.Google Scholar evaluated the effects of cooling and noted that “heat production rose progressively … in cooler and cooler chambers”, and that although crying increased “we never observed actual shivering”. Sinclair4Sinclair JC Heat production and thermoregulation in the small-for-date infant.Pediatr Clin N Am. 1970; 17: 147-158PubMed Google Scholar made similar observations. One wonders whether some mechanism other than hypothermia is responsible for shivering. Perhaps some pharmacological agent is responsible? Alexander5Alexander G Body temperature control in mammalian young.Br Med Bull. 1975; 31: 62-68PubMed Google Scholar proposed many years ago that shivering might occur if “non-shivering thermogenesis approached its full potential” and noted that sympatholytic drugs could block non-shivering thermogenesis and allow shivering to occur in young guinea-pigs. Alternatively, could the indication for amnioinfusion provide an explanation, for example, a stressed fetus releasing increased amounts of cortisol or catecholamines? Were any common factors present in these three cases, in addition to the mild degrees of hypothermia? Could this be related to some other aspect of modern obstetrical management, such as epidural anaesthesia?
Prognostic Factors in Non-Small-Cell Lung Cancer (NSCLC) Patients with Epidermal Growth Factor Receptor (EGFR) Mutations: Data from the Randomized Phase III Study Compared Gefitinib with Carboplatin Plus Paclitaxel (NEJ002)
Authors: Y. Minegishi, K. Kobayashi, M. Maemondo, A. Inoue, S. Sugawara, S. Ohizumi, H. Isobe, K. Hagiwara, S. Morita, T. Nukiwa, A. Gemma
Journal: Annals of Oncology (2012)
Inhibition of iron toxicity in human hepatocyte cultures by the pyoverdins PaA and Pf . INSERM U49 and Clinique des Maladies du Foie, CHRU Pontchaillou, Rennes; 1 ? Laboratoire de Biologie Cellulaire, Facult� de Pharmacie, Rennes; 2 ? Laboratoire de Chimie Microbienne, Universit� Louis Pasteur, Strasbourg, France
Journal: Hepatology (1995)

The effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on the liver of C57BL/6J mice is a model for clinical sporadic porphyria cutanea tarda (PCT). There is massive uroporphyria, inhibition of uroporphyrinogen decarboxylase (UROD) activity, and hepatocellular damage. A variety of evidence implicates the CYP1A2 enzyme as necessary for mouse uroporphyria. Here we report that, 5 weeks after a single oral dose of TCDD (75 μg/kg), Cyp1a2(+/+) wild-type mice showed severe uroporphyria and greater than 90% decreases in UROD activity; in contrast, despite exposure to this potent agent Cyp1a2(−/−) knockout mice displayed absolutely no increases in hepatic porphyrin levels, even after prior iron overload, and no detectable inhibition of UROD activity. Plasma levels of alanine-aminotransferase (ALT) and aspartate aminotransferase (AST)–although elevated in both genotypes after TCDD exposure–were significantly less in Cyp1a2(−/−) than in Cyp1a2(+/+) mice, suggesting that the absence of CYP1A2 also affords partial protection against TCDD-induced liver toxicity. Histological examination confirmed a decrease in hepatocellular damage in TCDD-treated Cyp1a2(−/−) mice; in particular, there was no bile duct damage or proliferation that in the Cyp1a2(+/+) mice might be caused by uroporphyrin. We conclude that CYP1A2 is both necessary and essential for the potent uroporphyrinogenic effects of TCDD in mice, and that CYP1A2 also plays a role in contributing to TCDD-induced hepatocellular injury. This study has implications for both the toxicity assessment of TCDD and the hepatic injury seen in PCT patients.
Biosatellite Space-Probes To Carry Monkeys, Microbes
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Dictionary of Medical Science. Containing a Full Explanation of the Various Subjects and Terms of Anatomy, Physiology, Medical Chemistry, Pharmacy, Pharmacology, Therapeutics, Medicine, Hygiene, Dietetics, Pathology, Bacteriology, Surgery, Ophthalmology, Otology, Laryngology, Dermatology, Gynecology, Obstetrics, Pediatrics, Medical Jurisprudence, Dentistry, Veterinary Science, etc.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reducing black neonatal mortality
Authors: S. Sepkowitz
Journal: JAMA (1985)

<h3>In Reply.—</h3> We thank Dr Sepkowitz for his perceptive comments on the bias that may have occurred in our neonatal mortality calculations because we excluded infants with unknown birth weight or gestational age. As he points out, the incidence of missing data on birth weight, gestational age, or both is highest among low-birth-weight, premature babies, who are at high risk of neonatal mortality. Furthermore, these infants with unrecorded data appear to be at even higher risk of mortality than other infants of the same weight or gestational age. Had we been able to include these infants in our neonatal mortality calculations, Dr Sepkowitz suggests that the true mortality rates would have been higher than those we reported, especially in the low-birth-weight, low-gestational-age cells. He further suggests that because of different rates of missing data for whites and blacks, the differences we noted between white and black mortality could have been
Book Review Manual of Standard Practice of Plastic and Maxillofacial Surgery . Prepared and edited by the Subcommittee on Plastic and Maxillofacial Surgery of the Committee on Surgery, Division of Medical Sciences, National Research Council, and representatives of the Medical Department, United States Army: Robert H. Ivy, M.D., chairman; John Staige Davis, M.D.; P. C. Lowery, M.D.; Joseph D. Eby, M.D.; Ferris Smith, M.D.; Brig. Gen. Leigh C. Fairbank, Medical Department U. S. A.; and Lt. Col. …
Journal: New England Journal of Medicine (1943)
Tuberculous Pericarditis
Authors: Bongani M. Mayosi, Lesley J. Burgess, Anton F. Doubell
Journal: Circulation (2005)

The incidence of tuberculous pericarditis is increasing in Africa as a result of the human immunodeficiency virus (HIV) epidemic. The primary objective of this article was to review and summarize the literature on the pathogenesis, diagnosis, and management of tuberculous pericarditis.We searched MEDLINE (January 1966 to May 2005) and the Cochrane Library (Issue 1, 2005) for information on relevant references. A "definite" diagnosis of tuberculous pericarditis is based on the demonstration of tubercle bacilli in pericardial fluid or on a histological section of the pericardium; "probable" tuberculous pericarditis is based on the proof of tuberculosis elsewhere in a patient with otherwise unexplained pericarditis, a lymphocytic pericardial exudate with elevated adenosine deaminase levels, and/or appropriate response to a trial of antituberculosis chemotherapy. Treatment consists of the standard 4-drug antituberculosis regimen for 6 months. It is uncertain whether adjunctive corticosteroids are effective in reducing mortality or progression to constriction. Surgical resection of the pericardium remains the appropriate treatment for constrictive pericarditis. The timing of surgical intervention is controversial, but many experts recommend a trial of medical therapy for noncalcific pericardial constriction, and pericardiectomy in nonresponders after 4 to 8 weeks of antituberculosis chemotherapy.Research is needed to improve the diagnosis, assess the effectiveness of adjunctive steroids, and determine the impact of HIV infection on the outcome of tuberculous pericarditis.
Changed criteria for diabetes need further research
Journal: BMJ (1998)

Changed criteria for diabetes need further researchIn 1997 the American Diabetes Association changed the diagnostic fasting plasma value for glucose from 7.8 to 7.0 mmol/l.For screening and epidemiological studies they no longer recommended the standard 75 g oral glucose tolerance test recommended by the WHO.The DECODE Study Group's reanalysis of epidemiological studies in eight European countries-more than 26 000 patients-found that the two diagnostic criteria agreed in only 431 of 1517 people classified as diabetic (p 371).Because of this reclassification the group says that the WHO should wait for results of further reanalyses, with focus on prognostic impact, before it considers adopting the ADA criteria.
ACIDIFIED MILKS
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pediatric Trauma
Authors: J. Alex Haller
Journal: JAMA (1983)

WE HEAR so much about the tragic loss of children from congenital heart disease, lung abnormalities, and malignancy that we have overlooked the fact that more than half of the children who die in the United States die as a result of serious injuries. Almost half of the deaths in children last year resulted from trauma, as compared with approximately one death in 20 in the general population due to injuries. The death of a child is, in itself, a tragedy, but crippling injuries to a child and the resulting need for rehabilitation may have a far greater impact on society and our health care system than a child's death will. The expenditure of resources and personnel and the economic loss caused by termination of work potential when a child is seriously handicapped are relatively enormous when compared with similar losses following injuries in adults. A child is usually affected